| Prev Close | 132.07 |
| Day Low/High | 130.19 / 132.39 |
| 52 Wk Low/High | 121.00 / 148.99 |
| Avg Volume | 6.88M |
Johnson & Johnson (JNJ)
130.31
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.66B |
| Market Cap | 350.65B |
| EPS | 5.70 |
| P/E Ratio | 24.46 |
| Div & Yield | 3.80 (2.77%) |
Latest News
Complacent Market Players Keep It Chill -- as Sparks Fly All 'Round
It is still a surprisingly sedate market, despite indexes sitting close to all-time highs, earnings season, possible interest-rate cuts and endless speculation about China trade.
Markets' Health, Facebook Libra Hearings, Trading Match Group: Market Recon
For those trading the FANG or FAANG names, and especially Facebook, Tuesday sets up as a day bearing exceptional levels of headline risk.
This Sedate Market Is an Ink Blot Test for Investors
The bulls will say this is healthy consolidation that will set up another leg higher, while the bears will say this is an indication of indecision and is a prelude to a rollover.
Jim Cramer: Don't Play Earnings Season, Invest in It
Here are my five rules for handling earnings season.
Johnson & Johnson: Key Points to Watch on the Charts
The stock has been bouncing off the 200-day moving average line.
10 Stocks and 10 ETFs for Socially Conscious Investors
Investors have shown an increasing interest in ESG Investing. These top investment vehicles emphasize strong business operations and social responsibilities.
Jim Cramer: A Tale of Two Stocks
I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.
Jim Cramer: This Is Now an Emotional Market
When traders are flailing and investors are drowning, examples work best to illustrate what happens before a bottom is reached.
Band-Aids Cannot Help Johnson & Johnson in This Decline
Let's take a serious look at the charts and indicators.
Water Company Dividend Kings That Quench the Thirst for Income
Dividend stock investors should look to have at least some exposure to this sector.
Jim Cramer: What to Buy and What to Avoid on Trump's Latest China Tweet
As usual, the stocks that bounce back first are the tech stocks with little Chinese exposure and the consumer packaged goods that just demonstrated good numbers.
Be Careful With Healthcare Stocks Here
Especially when healthcare CEOs discus political issues with analysts and reporters.
Johnson & Johnson and United Healthcare Face a Series of Obstacles
Recapping a big day of earnings for both names.
Fed's Evans Knows Nothing, China Q1 GDP, Trading Netflix: Market Recon
When Netflix reports earnings tonight, what will likely matter above all else for now will be subscriber growth.
How to Trade Johnson & Johnson During Earnings Week
The biggest challenge is even if JNJ beats and raises guidance, the overhang of litigation could still prevent overzealous trading.
Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy?
Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.
More Mud on Johnson & Johnson?
There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.
Jim Cramer: The Fed's Dramatic Sea Change and What It Means for Stocks Now
The best stocks to buy in this environment are the ones that have the greatest growth.
How to Play the Fed's Gift to the Markets (One Way Is With Netflix)
Wednesday was the first day that Netflix traded on above-average volume since Jan. 24.
The Rally in Johnson & Johnson Looks Like it has Run Its Course
Let's check out the charts.
Jim Cramer: 5 Examples Show Why Stock Investing Is So Difficult
Consider these five, right in front of you on this one day, so you get the perils of stock ownership and know how to handle them when they occur.
Digging Down on the Dow 30
Just 13 of the 30 Dow components are in clear uptrends.
Jim Cramer: AAPL Should Get Into Diabetes Treatment and KHC Should Invest in Pot
In this day and age, companies must be 'disruptors' or get left in the dust.
Jim Cramer: The Real Lesson of the 10-Year Bull Market Anniversary
Did the Fed aid Microsoft? No, Microsoft aided Microsoft. J&J aided J&J. Procter aided Procter.
Jim Cramer: No Room for Cynicism, JNJ's New Depression Drug Is Lifesaving
The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.
The Charts of Johnson & Johnson Do Not Yet Convince Me of the Bull Case
Let's look at the charts and indicators to round out the picture.
Jim Cramer: This Market Has a Terrible Case of Attention Deficit Disorder
I think this truly defines what has gone on with tech stocks since the latest reporting period began.
